rpl-17 Antibody

What is RPL17 and what cellular functions does it serve?

RPL17, also known as 60S ribosomal protein L17 or 60S ribosomal protein L23, is a component of the large 60S ribosomal subunit. Ribosomes are the organelles responsible for protein synthesis and consist of a small 40S subunit and a large 60S subunit. Together, these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins . RPL17 belongs to the L22P family of ribosomal proteins and is located in the cytoplasm. It functions as an essential component in the ribosomal machinery, participating in the synthesis of proteins within the cell . This protein has been referred to as rpL23 due to its amino acid identity with ribosomal protein L23 from Halobacterium marismortui, though its official symbol is RPL17 . The protein has a calculated molecular weight of approximately 21397 Da .

Which applications are most validated for RPL17 antibodies?

According to the available research data, RPL17 antibodies have been extensively validated for several applications:

Western blot applications are particularly well-validated, with antibodies successfully detecting RPL17 in human and mouse cell lines including MO7e human megakaryocytic leukemic cells and BaF3 mouse pro-B cells, typically showing a band at approximately 22 kDa . Immunohistochemistry applications have also shown specific staining localized to the cytoplasm of various cell types, including acinar cells in human pancreas samples . Different antibodies may require optimization for specific applications, with recommended dilution ranges typically between 1:50-1:200 for IHC and ICC, and 1:500-1:1000 for Western blot applications .

What species reactivity should researchers consider when selecting RPL17 antibodies?

When selecting RPL17 antibodies, researchers should carefully consider the species reactivity profile based on their experimental models:

Most commercially available RPL17 antibodies demonstrate confirmed reactivity with human RPL17 . Many antibodies also show cross-reactivity with mouse and rat RPL17, making them suitable for comparative studies across these common laboratory animal models . Some antibodies have predicted reactivity with bovine and rabbit RPL17, though these may require additional validation by researchers .

The documented species reactivity varies between antibody products. For instance, the monoclonal antibody (clone 702142) detects both human and mouse RPL17 in Western blot applications , while some polyclonal antibodies have broader species reactivity including human, mouse, and rat . When working with less common experimental species, researchers should prioritize antibodies with documented or predicted cross-reactivity for their target organism or consider testing multiple antibodies to identify optimal performance.

How should RPL17 antibodies be properly stored and handled?

Proper storage and handling of RPL17 antibodies is critical for maintaining antibody performance and extending shelf life:

For long-term storage, RPL17 antibodies should be maintained at -20°C in small aliquots to prevent repeated freeze-thaw cycles, which can degrade antibody performance . For short-term storage and frequent use (up to one month), refrigeration at 2-8°C is generally acceptable . When working with lyophilized antibodies, reconstitution should be performed in sterile PBS to a final concentration of 0.5 mg/mL unless otherwise specified by the manufacturer .

Antibody formulations typically contain preservatives such as sodium azide (often at 0.02-0.09%) and stabilizers like glycerol (up to 50%), which help maintain antibody integrity . These components should be considered when designing experiments, as some may interfere with certain applications. Researchers should avoid repeated freeze-thaw cycles by preparing small working aliquots upon first thawing the antibody. Prior to use, allow the antibody to equilibrate to room temperature and gently mix by inversion or light vortexing to ensure homogeneity without causing protein denaturation.

What are the optimal dilution ranges for different RPL17 antibody applications?

Determining the optimal dilution for RPL17 antibodies is crucial for experimental success and resource efficiency. Based on validated protocols, the following dilution ranges provide starting points for optimization:

For Western blot applications, RPL17 antibodies typically perform well at dilutions ranging from 1:500 to 1:1000 . More concentrated preparations may be required for detecting low abundance targets, while higher dilutions might be sufficient for abundant expression. For immunohistochemistry applications, including paraffin-embedded tissue sections (IHC-P), a dilution range of 1:50 to 1:200 is generally recommended . RPL17 antibodies used in immunocytochemistry (ICC) applications typically require similar dilutions to IHC, with recommended ranges of 1:50 to 1:200 .

For optimal results, researchers should perform dilution series experiments with their specific samples and detection systems. Factors that may influence optimal dilution include the abundance of RPL17 in the sample, the sensitivity of the detection system, the specific antibody affinity, and the presence of potential cross-reactive proteins. A titration experiment using a range of dilutions centered around the manufacturer's recommendation will help identify the optimal working concentration for each specific application and experimental system.

How can researchers validate RPL17 antibody specificity?

Validating antibody specificity is essential for generating reliable and reproducible research data with RPL17 antibodies:

Positive Controls: Use cell lines or tissues known to express RPL17 at detectable levels. Pancreatic tissue and various cell lines including MO7e human megakaryocytic leukemic cells and BaF3 mouse pro-B cells have been validated as positive controls for RPL17 expression . The RPL17 protein has been shown to be expressed in multiple tissues including pancreas, lung, colon, cystic duct, gall bladder, kidney, and liver. It is also highly expressed in various pancreatic tumor cell lines .

Western Blot Verification: Confirm that the antibody detects a band of the expected molecular weight (approximately 21-22 kDa for RPL17) . The observation of a single predominant band suggests specificity, while multiple bands may indicate cross-reactivity.

Blocking Peptide Competition: Perform parallel experiments where the antibody is pre-incubated with the immunizing peptide. For RPL17 antibodies raised against synthetic peptides (e.g., those corresponding to amino acids 139-184 or 156-184 of human RPL17), the specific blocking peptide can often be purchased separately . Disappearance of signal in the blocked sample confirms specificity.

Knockdown Validation: Use siRNA or shRNA to reduce RPL17 expression and confirm corresponding reduction in antibody signal. This approach provides strong evidence for antibody specificity, especially when combined with other validation methods.

What are the most common technical challenges when using RPL17 antibodies?

Researchers frequently encounter several technical challenges when working with RPL17 antibodies:

Background Signal: Being a ribosomal protein, RPL17 is abundantly expressed in most cell types, which can sometimes result in high background staining, particularly in IHC and ICC applications. To address this, optimize blocking conditions (use 3-5% BSA or normal serum from the same species as the secondary antibody) and consider longer blocking times (1-2 hours). Carefully titrate primary antibody concentrations, as excessive antibody can contribute to non-specific binding. For IHC applications, heat-induced epitope retrieval using basic antigen retrieval reagents has been shown to improve specific staining while reducing background .

Cross-Reactivity with Ribosomal Proteins: Due to structural similarities among ribosomal proteins, cross-reactivity can occur. Select antibodies that target unique regions of RPL17, such as those targeting the C-terminal region (amino acids 156-184) . When possible, confirm results with multiple antibodies targeting different epitopes of RPL17.

Fixation Effects: Different fixation methods can affect epitope accessibility and antibody binding. For RPL17 detection in fixed tissues, immersion-fixed paraffin-embedded sections have been successfully used with heat-induced epitope retrieval . Compare different fixation protocols (PFA, methanol, or acetone) if inconsistent results are observed across sample preparations.

How does antibody performance differ between monoclonal and polyclonal RPL17 antibodies?

Monoclonal and polyclonal RPL17 antibodies demonstrate distinct performance characteristics that researchers should consider based on their specific applications:

Monoclonal RPL17 Antibodies:
Monoclonal antibodies such as clone 702142 offer high specificity for a single epitope of RPL17 . This provides consistent lot-to-lot reproducibility, making them excellent for longitudinal studies requiring standardized detection. Monoclonal antibodies typically demonstrate lower background in Western blot applications, producing clean bands at the expected 22 kDa size. They excel in applications requiring high specificity but may be less sensitive when target protein expression is low or when epitopes are masked by fixation or protein interactions. Monoclonal antibodies have been particularly well-validated for direct ELISA applications detecting human RPL17 .

What approaches can be used to investigate RPL17's role in ribosome assembly and function?

Investigating RPL17's role in ribosome assembly and function requires sophisticated experimental approaches:

Co-immunoprecipitation (Co-IP): RPL17 antibodies can be used to pull down ribosomal complexes and identify interacting partners through mass spectrometry. This approach can reveal novel interactions within the ribosomal machinery or with regulatory factors. Polyclonal antibodies are often preferred for immunoprecipitation due to their ability to recognize multiple epitopes, increasing pull-down efficiency .

Polysome Profiling: Combine sucrose gradient centrifugation with Western blot analysis using RPL17 antibodies to examine the protein's distribution across different ribosomal subpopulations (40S, 60S, 80S, and polysomes). This provides insights into RPL17's role in ribosome assembly and translation dynamics. When performing these experiments, use ribonuclease inhibitors to prevent degradation of ribosomal RNA, which could disrupt complex integrity.

Proximity Labeling: Employ techniques such as BioID or APEX2 with RPL17 as the bait protein to identify proteins in close proximity within the cellular environment. This can reveal transient interactions during ribosome assembly that might be missed by traditional co-IP approaches.

Ribosome Footprinting: Combine with RPL17 depletion or mutation studies to determine how alterations in this protein affect ribosome positioning on mRNAs, potentially revealing roles in translation regulation of specific transcripts.

What considerations are important when using RPL17 antibodies for studying cancer and disease models?

RPL17 has been implicated in various disease processes, particularly in cancer research, requiring specific considerations:

Expression Level Variations: RPL17 shows differential expression across cancer types and degrees of differentiation. Studies have documented high expression levels in various pancreatic tumor cell lines with different differentiation statuses, including well-differentiated (HPAF, COLO 357, Capan-1), moderately differentiated (T3M-4, AsPc-1, BxPc-3), and poorly differentiated (MIA PaCa-2) pancreatic tumor cells . When studying cancer models, include appropriate normal tissue controls and multiple cancer cell lines representing different malignancy stages.

Subcellular Localization: While primarily cytoplasmic, changes in RPL17 localization may occur in disease states. For accurate subcellular localization studies, combine immunofluorescence using RPL17 antibodies with markers for specific organelles. In normal tissues, specific staining for RPL17 has been localized to the cytoplasm of cells, such as acinar cells in pancreatic tissue .

Post-translational Modifications: Disease processes may alter post-translational modifications of RPL17. Consider using antibodies specific to modified forms or complement antibody studies with mass spectrometry to identify disease-specific modifications.

Extraribosomal Functions: Growing evidence suggests ribosomal proteins may have functions beyond protein synthesis. When investigating potential extraribosomal roles of RPL17 in disease, subcellular fractionation combined with immunoblotting can help identify non-ribosomal pools of the protein that may be involved in alternative cellular processes.

How can RPL17 antibodies be optimized for multiplexed immunofluorescence studies?

Multiplexed immunofluorescence allows simultaneous visualization of multiple proteins and is particularly valuable for studying RPL17 in context with other cellular components:

Antibody Compatibility: When designing multiplexed panels, ensure compatibility between RPL17 antibodies and other target antibodies by selecting primary antibodies raised in different host species to avoid cross-reactivity of secondary antibodies. For instance, rabbit polyclonal anti-RPL17 antibodies can be paired with mouse, goat, or rat antibodies against other targets.

Sequential Staining Protocols: For complex multiplexing, implement sequential staining protocols with intermediate stripping or quenching steps. Begin with the least sensitive target (typically abundant proteins like RPL17) and progress to more sensitive detections. Document complete stripping of previous antibody layers before applying subsequent antibodies.

Spectral Considerations: Select fluorophores with minimal spectral overlap for conjugation to secondary antibodies. For RPL17 visualization alongside other ribosomal or nuclear markers, consider using fluorophores in distinct spectral regions (e.g., Alexa Fluor 488, 555, 647).

Controls for Multiplexed Studies: Include single-stained controls for each antibody to confirm signal specificity and absence of bleed-through. Additionally, implement antibody order controls to verify that the detection sequence does not affect signal intensity or localization patterns.

What are effective strategies for overcoming weak or absent RPL17 signal in Western blots?

When encountering weak or absent RPL17 signal in Western blot applications, consider these methodological adjustments:

Sample Preparation Optimization: Ensure complete protein extraction by using buffers containing strong detergents (1% SDS) and reducing agents (DTT or β-mercaptoethanol). RPL17, as a ribosomal protein, may be tightly associated with ribosomal RNA, requiring thorough extraction methods. Consider including RNase treatment in your lysis buffer to release RPL17 from ribosomal complexes.

Transfer Conditions: Optimize transfer conditions specifically for lower molecular weight proteins like RPL17 (21-22 kDa). Use lower methanol concentrations (10-15%) in transfer buffer to improve transfer efficiency of smaller proteins. Consider reducing transfer time or voltage to prevent the protein from transferring through the membrane.

Antibody Concentration Adjustment: If using the recommended dilution range (1:500-1:1000) produces weak signals, increase antibody concentration incrementally (e.g., try 1:250). Extended primary antibody incubation (overnight at 4°C) can also improve signal detection for some antibodies.

Enhanced Detection Systems: Switch to more sensitive detection systems such as enhanced chemiluminescence (ECL) with longer exposure times or consider fluorescent secondary antibodies with imaging systems that offer greater sensitivity and quantitative capabilities.

How can researchers address non-specific binding in immunohistochemistry applications?

Non-specific binding presents a common challenge in immunohistochemistry applications with RPL17 antibodies:

Optimized Antigen Retrieval: Heat-induced epitope retrieval using antigen retrieval reagents appropriate for RPL17 has been shown to improve specific staining . For RPL17 detection, basic antigen retrieval reagents have proven effective. Optimize both the retrieval solution pH and heating time/temperature for your specific tissue samples.

Enhanced Blocking Protocols: Implement stringent blocking procedures using 3-5% BSA or normal serum from the secondary antibody species. For tissues with high endogenous biotin (like liver, kidney), use avidin-biotin blocking steps if employing biotin-based detection systems. Consider adding 0.1-0.3% Triton X-100 to blocking buffers to reduce hydrophobic interactions while improving antibody penetration.

Antibody Absorption: Pre-absorb the primary RPL17 antibody with acetone powder prepared from tissues or cells not expressing the target to remove antibodies that might bind to common epitopes. This is particularly valuable for polyclonal antibodies that may contain diverse antibody populations.

Isotype Controls: Include isotype controls matched to your primary antibody to distinguish between specific binding and Fc receptor-mediated binding. For monoclonal RPL17 antibodies, use the appropriate mouse IgG isotype control; for rabbit polyclonal antibodies, use normal rabbit IgG.

Titration Experiments: Conduct systematic dilution series experiments to identify the optimal antibody concentration that maximizes specific signal while minimizing background. For RPL17 antibodies in IHC applications, test dilutions across the recommended range (1:50-1:200) and potentially beyond in both directions.

What approaches can resolve cross-reactivity issues with RPL17 antibodies?

Cross-reactivity can complicate RPL17 antibody applications, particularly given its membership in a family of structurally similar ribosomal proteins:

Epitope-Specific Antibody Selection: Choose antibodies targeting unique regions of RPL17 rather than conserved domains shared among ribosomal proteins. Antibodies targeting the C-terminal region of RPL17 (amino acids 156-184) have demonstrated good specificity . Review the immunogen information provided by manufacturers – synthetic peptide-derived antibodies often offer greater specificity than those raised against full-length proteins.

Preabsorption Validation: Conduct preabsorption controls by incubating the antibody with excess immunizing peptide prior to application. Complete signal elimination confirms specificity, while partial reduction may indicate cross-reactivity with related proteins. For RPL17 antibodies, blocking peptides corresponding to the immunizing sequence may be available for purchase .

Orthogonal Validation: Confirm results using alternative methods targeting RPL17. Compare protein detection results with mRNA expression data from qPCR or RNA-seq. Agreement between protein and transcript levels increases confidence in antibody specificity.

Genetic Models: Where possible, use cells with genetic knockdown/knockout of RPL17 as negative controls. Complete signal loss in these models provides strong evidence for antibody specificity. For transient validation, siRNA knockdown of RPL17 followed by Western blot analysis can assess the specificity of bands detected by the antibody.

How can RPL17 antibodies contribute to understanding extraribosomal functions of ribosomal proteins?

Beyond their canonical roles in protein synthesis, ribosomal proteins including RPL17 are increasingly recognized for their extraribosomal functions:

Subcellular Fractionation Studies: Use RPL17 antibodies in combination with subcellular fractionation to identify non-ribosomal pools of the protein that may be involved in alternative cellular processes. Compare detection patterns between cytoplasmic, nuclear, mitochondrial, and other cellular fractions. Differential distribution patterns across fractions may indicate potential extraribosomal functions.

Interactome Analysis: Employ RPL17 antibodies for immunoprecipitation followed by mass spectrometry to identify novel interaction partners outside the ribosomal complex. Analysis of these interactions under different cellular conditions (stress, differentiation, disease states) may reveal condition-specific functions of RPL17. Polyclonal antibodies targeting different regions of RPL17 may be more suitable for capturing diverse protein complexes .

Stress Response Investigation: Apply RPL17 antibodies to study potential roles in cellular stress responses. Examine changes in RPL17 localization, post-translational modifications, or interaction partners following exposure to various stressors (oxidative stress, nutrient deprivation, heat shock, DNA damage). These studies may reveal stress-specific functions beyond ribosome assembly.

Disease-Specific Studies: Investigate RPL17's potential involvement in disease processes beyond translation regulation. The protein is expressed in numerous tissues including pancreas, lung, colon, and liver, with variable expression in pancreatic tumor cell lines of different differentiation statuses . RPL17 antibodies can help track expression and localization changes across disease progression stages.

What emerging technologies can enhance RPL17 antibody applications in research?

Several cutting-edge technologies offer opportunities to expand RPL17 antibody applications:

Super-Resolution Microscopy: Apply techniques such as STORM, PALM, or STED microscopy with RPL17 antibodies to visualize ribosome distribution and dynamics at nanoscale resolution. These approaches can reveal previously undetectable spatial arrangements of ribosomes and potential co-localization with other cellular components. Consider using directly labeled primary antibodies or nanobody alternatives to minimize the distance between fluorophore and target for optimal resolution.

Proximity Labeling Proteomics: Combine RPL17 antibodies with emerging proximity labeling techniques (BioID, APEX2, TurboID) to identify proteins in close spatial proximity to RPL17 in living cells. This approach can reveal transient or weak interactions that might be lost in traditional co-immunoprecipitation experiments, potentially uncovering novel functions or regulatory mechanisms.

Single-Cell Proteomics: Utilize RPL17 antibodies in developing single-cell proteomic techniques to examine cell-to-cell variability in ribosome composition and RPL17 expression. These approaches can reveal population heterogeneity that might be masked in bulk analyses, particularly in complex tissues or disease states where cellular subpopulations may exhibit distinct ribosomal profiles.

CRISPR-Based Genomic Tagging: Combine endogenous tagging of RPL17 using CRISPR-Cas9 with highly specific antibodies against the tag to achieve improved specificity and versatility in tracking RPL17 dynamics. This approach enables live-cell imaging of RPL17 and can be combined with other genomic modifications to investigate functional relationships.